scholarly journals Mesenchymal stem cell treatment for refractory pediatric rheumatic diseases: A single center case series

2020 ◽  
Author(s):  
Stephen Chee-Yung Wong ◽  
Leah C Medrano ◽  
Alice D Hoftman ◽  
Olcay Y Jones ◽  
Deborah K McCurdy
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Pediatric Rheumatology ◽  
Case Series ◽  
Infusion Therapy ◽  
Mesenchymal Stem Cell Transplantation ◽  
Mesenchymal Stem Cell Therapy

Abstract Background:Pediatric rheumatic disease treatment has seen a surge in innovative therapies including numerous biologic medications that show great potential. Yet, many children with advanced disease are not able to reach remission on available treatment. Mesenchymal stem cells have immunomodulatory properties, and transplantation of these stem cells have been used to successfully treat immunologic conditions like graft-versus-host disease. Mesenchymal stem cell research in adult lupus has been encouraging, but there is a lack of studies in pediatric rheumatology. This retrospective case series will highlight three children with refractory autoimmune disease who received mesenchymal stem cell therapy and review the potential benefits and risks of this emerging treatment modality.Case Presentation:Three children with established diagnoses of systemic lupus erythematosus, mixed connective tissue disease and juvenile idiopathic arthritis were under the care of pediatric rheumatology at a large, tertiary-care, teaching institution for many years. Multiple non-biologic and biologic disease-modifying anti-rheumatic drugs failed to significantly decrease disease activity, and as a result, the families chose to undergo mesenchymal stem cell therapy. After transplantation, all children improved and were able to taper off conventional immunosuppressive drugs. No serious adverse events occurred. Conclusion:The three cases presented in this study reflect comparable beneficial outcomes and minimal risks published in adult studies. Mesenchymal stem cell transplantation is a promising adjunctive treatment option that necessitates further research and development of standardized infusion therapy protocols.

Should Mesenchymal Stem Cell Therapy be used in the treatment of COVID-19?

2020 ◽  
Vol 54 ◽  
Author(s):  
Namnama P. Villarta-De Dios ◽  
Evelyn S. Osio-Salido
Keyword(s):  
Stem Cells ◽  
Randomized Controlled Trial ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Standard Treatment ◽  
Controlled Trial ◽  
Mesenchymal Stem Cell Therapy ◽  
Randomized Controlled

KEY FINDINGSThere is some short-term benefit from the use of mesenchymal stem cell therapy for severe COVID-19 in a lowquality, small randomized controlled trial (RCT). Further studies, ideally with good quality RCTs, are needed toconfirm benefit and safety.• Mesenchymal stem cells (MSCs) are non-hematopoietic adult stem cells that are able to self-renew anddifferentiate into various cells of any cell lineage. MSCs have the ability to migrate (homing) to damaged tissuefor repair and regeneration, as well as signal other cells to help in tissue repair. It can effect cellular differentiation,consequently shifting the immune system from Th1 to Th2 responses.1,2• A recent review showed improved disease-associated parameters in experimental acute respiratory distresssyndrome (ARDS).3• We found three studies (one case report, one prospective cohort, and one small randomized controlled trial)reporting the effects of MSC on COVID-19. Based on low-quality evidence, it appeared that human umbilicalcord blood-derived MSC, given after failure to improve with standard treatment, had beneficial effects in termsof earlier onset of clinical improvement among individuals with severe or critical COVID-19. However, 28-dayclinical improvement and mortality were not significantly different compared to standard treatment. There wasno reported adverse reaction.• There are 52 registered and ongoing clinical trials to investigate the efficacy and safety of mesenchymal stemcells as treatment for COVID-19.• Mesenchymal stem cell therapy is not included in any of the existing guidelines for the treatment of COVID-19.

scholarly journals Will Mesenchymal Stem Cell Therapy Be Effective In COVID-19?

2021 ◽  
Vol 11 (6) ◽  
pp. 281-285
Author(s):  
Srinivas Kalai ◽  
M Senthil ◽  
R Sambath Kumar ◽  
R Kameshwaran
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Immune System ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Umbilical Cord ◽  
Stem Cell Therapy ◽  
Human Umbilical Cord ◽  
Cytokine Storm ◽  
Mesenchymal Stem Cell Therapy

Background: The World Health Organization (WHO) reports that the outbreak of the deadly virus had been noted almost in all the countries worldwide. Newly no standard therapies are available to combat the situation and this remains the major challenge for healthcare professionals to provide effective treatment against the life-threatening condition. A potential regenerative medicine method using the infusion of stem cells for the treatment of lung disorders has been reported. This review attempted to explore the immunomodulatory characteristics of Mesenchymal Stem Cells (MSCs) and how these properties make them beneficial for the treatment of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) patients. Objectives: To study the effect of Mesenchymal Stem Cell therapy in treating COVID-19. Methodology: A literature search was conducted to identify recent research relating to the review's goal of analyzing the relevance of stem cells in battling SARS-CoV-2. Results: The MSCs settle in the lungs intravenously to enhance the pulmonary microenvironment, minimize immune system over-activation, and encourage regeneration of damaged lung tissues. Its therapeutic properties like immune response inhibition play a major role in combating viruses. The avoidance of cytokine storm is the most important stage in COVID-19 therapy. Their potent immunomodulatory properties have positive effects in avoiding or attenuating the cytokine storm and assisting in the regeneration of injured lung tissues/other organs. Conclusion: Intravenous human Umbilical Cord-Mesenchymal Stem Cell therapy (hUC-MSC) transplantation is a safe and effective technique that may be used as a restoration and prioritized therapeutic option for treating severe COVID-19. Keywords: Covid-19, human Umbilical Cord-Mesenchymal Stem Cell therapy (huc-msc), Immune system.

Application of Bone Marrow–Derived Mesenchymal Stem Cells for Muscle Healing After Contusion Injury in Mice

2020 ◽  
Vol 48 (5) ◽  
pp. 1226-1235 ◽  
Author(s):  
Chih-Hao Chiu ◽  
Tsan-Hsuan Chang ◽  
Shih-Sheng Chang ◽  
Gwo-Jyh Chang ◽  
Alvin Chao-Yu Chen ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Mesenchymal Stem Cell Therapy ◽  
Contusion Injury ◽  
Fast Twitch

Background: Skeletal muscle injuries are very common in sports medicine. Conventional therapies have limited clinical efficacy. New treatment methods should be developed to allow athletes to return to play with better function. Purpose: To evaluate the in vitro differentiation potential of bone marrow–derived mesenchymal stem cells and the in vivo histologic and physiologic effects of mesenchymal stem cell therapy on muscle healing after contusion injury. Study Design: Controlled laboratory study. Methods: Bone marrow cells were flushed from both femurs of 5-week-old C57BL/6 mice to establish immortalized mesenchymal stem cell lines. A total of 36 mice aged 8 to 10 weeks were used to develop a muscle contusion model and were divided into 6 groups (6 mice/group) on the basis of the different dosages of IM2 cells to be injected (0, 1.25 × 105, and 2.5 × 105 cells with/without F-127 in 100 μL of phosphate-buffered saline). Histological analysis of muscle regeneration was performed, and the fast-twitch and tetanus strength of the muscle contractions was measured 28 days after muscle contusion injury, after injections of different doses of mesenchymal stem cells with or without the F-127 scaffold beginning 14 days after contusion injury. Results: The mesenchymal stem cell–treated muscles exhibited numerous regenerating myofibers. All the groups treated with mesenchymal stem cells (1.25 × 105 cells, 2.5 × 105 cells, 1.25 × 105 cells plus F-127, and 2.5 × 105 cells plus F-127) exhibited a significantly higher number of regenerating myofibers (mean ± SD: 111.6 ± 14.77, 133.4 ± 21.44, 221.89 ± 32.65, and 241.5 ± 25.95, respectively) as compared with the control group and the control with F-127 (69 ± 18.79 and 63.2 ± 18.98). The physiologic evaluation of fast-twitch and tetanus strength did not reveal differences between the age-matched uninjured group and the groups treated with various doses of mesenchymal stem cells 28 days after contusion. Significant differences were found between the control group and the groups treated with various doses of mesenchymal stem cells after muscle contusion. Conclusion: Mesenchymal stem cell therapy increased the number of regenerating myofibers and improved fast-twitch and tetanus muscle strength in a mouse model of muscle contusion. However, the rapid decay of transplanted mesenchymal stem cells suggests a paracrine effect of this action. Treatment with mesenchymal stem cells at various doses combined with the F-127 scaffold is a potential therapy for a muscle contusion. Clinical Relevance: Mesenchymal stem cell therapy has an effect on sports medicine because of its effects on myofiber regeneration and muscle strength after contusion injury.

scholarly journals Nitric oxide modulation in neuroinflammation and the role of mesenchymal stem cells

2021 ◽  
pp. 153537022199705
Author(s):  
Pan M Liy ◽  
Nur Nabilah A. Puzi ◽  
Shinsmon Jose ◽  
Sharmili Vidyadaran
Keyword(s):  
Nitric Oxide ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Neuronal Damage ◽  
Mesenchymal Stem Cell Therapy

Nitric oxide is a versatile mediator formed by enzymes called nitric oxide synthases. It has numerous homeostatic functions and important roles in inflammation. Within the inflamed brain, microglia and astrocytes produce large amounts of nitric oxide during inflammation. Excessive nitric oxide causes neuronal toxicity and death and mesenchymal stem cells can be used as an approach to limit the neuronal damage caused by neuroinflammation. Mesenchymal stem cell therapy ameliorates inflammation and neuronal damage in disease models of Alzheimer’s disease, Parkinson’s disease, and other neuroinflammatory disorders. Interestingly, we have reported that in vitro, mesenchymal stem cells themselves contribute to a rise in nitric oxide levels through microglial cues. This may be an undesirable effect and highlights a possible need to explore acellular approaches for mesenchymal stem cell therapy in the central nervous system.

Sign in / Sign up

Export Citation Format

Share Document